SeaStar Medical Holding Corporation announced its financial results for the second quarter of 2025, reporting net revenue of approximately $0.3 million. This revenue was generated from sales of the QUELIMMUNE pediatric SCD therapy, which was launched as a commercial product in July 2024 following its approval under a Humanitarian Device Exemption. The company reported a net loss of approximately $2.0 million for the three-month period ending June 30, 2025. This represents a decrease compared to the net loss of $3.2 million reported for the same period in 2024. The reduction in research and development expenses, from $2.3 million in 2024 to $1.0 million in 2025, contributed to this change, primarily due to lower preclinical and clinical trial expenses, consulting expenses, and personnel costs. SeaStar Medical also highlighted several business updates, including the enrollment of 31 additional patients in the NEUTRALIZE-AKI trial, the adoption of QUELIMMUNE therapy by three new top-rated U.S.-based children's hospitals, and positive survival results from the first 20 pediatric patients treated with QUELIMMUNE in a commercial setting. Cash at hand as of June 30, 2025, was $6.3 million, an increase from $1.8 million at the end of 2024. Additionally, the company raised an extra $8.4 million in July and August 2025 through two registered direct offerings, which are intended to support ongoing operations into 2026.